1 / 11

Data Sharing / IRB Issues

Data Sharing / IRB Issues. Data to be shared (Raw genotypes? Summary data?) Timing of data sharing Protected time for CARE Consortium? How long? Publications Committee? Data Access Committee? Is the Data Enclave model a solution? Ancillary Study Applications …Staged approach.

winka
Download Presentation

Data Sharing / IRB Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Data Sharing / IRB Issues Data to be shared(Raw genotypes? Summary data?) Timing of data sharing Protected time for CARE Consortium? How long? Publications Committee? Data Access Committee? Is the Data Enclave model a solution? Ancillary Study Applications …Staged approach

  2. Are there funds to address the additional burden at each Coordinating Center?

  3. Data to be shared • Raw genotypes • Analytic advantages • Risks • Protections • Summary data • Possible formats • Interacting genes?

  4. Timing of data sharing? • Initial phase (current ancillary studies proposal) • Second phase (all genotypes, phenotypes) • Protected time for CARE Consortium? • Any scientific reason? • How long? • Data Enclave • Beyond Data Enclave?

  5. Data Enclave • IRB-approved projects only • Confidentiality agreement (to cover non-identification, etc.) • For-profit entities (Third party agreements?) • Access tailored to consent • Will a data enclave be adequate?

  6. Publications Committee • During CARE Consortium “grace period”? • After any grace period?

  7. Data Access Committee • During CARE Consortium “grace period”? • After any grace period? • Would a Data Steward be adequate?

  8. Are there funds to address the additional burden at each Coordinating Center?

  9. Additional Issues • Manuscript-driven data release (CARDIA, CHS) (?) • Progress reports • Central training documentation (IRB, HIPAA) (?) • Results reporting • Acknowledgements • Statement of support

  10. Additional Issues (cont’d) • Manuscript titles • Cohort publications procedures (reporting, etc.) • Verification of analyses (CARDIA, MESA, others?) • Return of data to cohorts • Can cohorts then initiate independent analyses?

  11. Ancillary Study Applications • Phase I • Can we obtain full DNA release for this limited first stage? • Phase II • How soon can we start work on this? • What obstacles must be surmounted?

More Related